Evogene (EVGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.70M
Last updated: Nov 17, 2026 at 4:39 PM ET
Evogene (EVGN) Statistics
Evogene (EVGN) has a market cap of $6.70M. It kept -694.19% of revenue as net income over the last 12 months. Its share count is up 68.84% from a year earlier.
Total Valuation
| Market Cap | $6.70M |
|---|---|
| Latest price (Nov 17, 2026) | $0.34 |
Key Dates
The next earnings report is expected on Nov 18, 2026, covering the quarter ending Sep 30, 2026.
| Next Earnings Date | Nov 18, 2026 (expected) |
|---|---|
| Last Earnings Date | Aug 18, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 3.2x. Its year-end P/S ranged from 1.3x to 519.9x from 2016 to 2025.
| P/S Ratio | 3.2x |
|---|---|
| Forward P/S | 4.7x |
Price Statistics
The stock is down 71.89% over 52 weeks and trades 15.00% below its 50-day average.
| Beta (1Y) | 1.29 |
|---|---|
| 52-Week Change | -71.89% |
| 1-Month Change | -7.58% |
| 3-Month Change | -43.40% |
| 6-Month Change | -54.29% |
| 5-Year Change | -98.56% |
| 10-Year Change | -99.38% |
| Total Return (1Y) | -71.89% |
| Total Return (3Y CAGR) | -62.78% |
| Total Return (5Y CAGR) | -56.18% |
| Max Drawdown (1Y) | -77.42% |
| Max Drawdown (3Y) | -97.23% |
| Sharpe Ratio (1Y) | -1.45 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $0.40 |
| 200-Day Average | $0.62 |
| 52-Week Range | $0.25 to $1.26 |
| RSI (14 Days) | 44.6 |
| Average Volume (20 Days) | 584.88K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.57x current liabilities.
| Current Ratio | 3.57x |
|---|---|
| Quick Ratio | 3.54x |
| Interest Coverage | -2.77x |
Returns and Efficiency
| Return on Assets (ROA) | -67.51% |
|---|---|
| Return on Capital Employed (ROCE) | -129.47% |
| ROA (5Y Average) | -42.86% |
| Asset Turnover | 0.06x |
| Inventory Turnover | 21.84x |
| Receivables Turnover | 1.25x |
| Cash Conversion Cycle | 255 days |
Scores
EVGN has an Altman Z-Score of -32.41, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -32.41 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $1.31M over the last 12 months is down 80.43% from the 12 months before.
| Revenue | $1.31M |
|---|---|
| Revenue Growth (YoY) | -80.43% |
| Gross Profit | -$1.62M |
| Operating Income | -$13.53M |
| Pretax Income | -$15.56M |
| Net Income | -$9.07M |
| EBITDA | -$12.56M |
| EBIT | -$13.46M |
| Reported EPS (TTM) | -$1.82 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
| Cash and Equivalents | $9.35M |
|---|---|
| Working Capital | $7.81M |
| Shareholder Equity | -$3.29M |
| Total Assets | $13.44M |
| Total Liabilities | $7.67M |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $28.66K of capital spending, operating cash flow left -$11.56M of free cash flow.
| Operating Cash Flow | -$11.54M |
|---|---|
| Capital Expenditures | $28.66K |
| Free Cash Flow | -$11.56M |
| FCF Per Share | -$0.64 |
| Depreciation and Amortization | $895.00K |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -1034.97%.
| Gross Margin | -123.87% |
|---|---|
| Operating Margin | -1034.97% |
| Pretax Margin | -1190.74% |
| Net Margin | -694.19% |
| EBITDA Margin | -961.36% |
| EBIT Margin | -1029.84% |
| FCF Margin | -884.79% |
| Gross Margin (5Y Average) | 32.87% |
Growth
Revenue grew 32.01% a year over 3 years.
| Revenue Growth (3Y CAGR) | +32.01% |
|---|---|
| Revenue Growth (5Y CAGR) | +29.94% |
Dividends and Yields
EVGN does not pay a dividend. Its free cash flow yield is -278.71%.
| FCF Yield | -278.71% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-10 reverse split on Jul 25, 2024.
| Last Split Date | Jul 25, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 6 similar companies, EVGN has the 6th highest P/S.
P/S RatioPeer median 9.8x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -63.21%
| P/S Ratio | 3.2x vs 9.8x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -80.43% vs -63.21% median |
Analyst Forecast
Consensus estimates put revenue growth at -17.85% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -17.85% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About EVGN
What is EVGN's market cap?
Evogene has a market cap of $6.70M.
How many shares of EVGN are outstanding?
Evogene has 12.20M shares outstanding. The count is up 68.84% from a year earlier.
Does EVGN pay a dividend?
No. Evogene does not pay a dividend.
EVGN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors